Zobrazeno 1 - 10
of 98
pro vyhledávání: '"L. J. Klaff"'
Autor:
M B Manning, D A Streja, C Keller, C H Chung, P L Beckett, A Özdemir, Y M Cho, I Colin, L J Aronne, Erik Christiansen, Markus Laimer, L Van Gaal, S N Lederman, T M O'Connor, L J Klaff, S Aronoff, S H Baik, A V Murray, Signe O R Wallenstein, N A Godbole, H O Høivik, Dilek Gogas Yavuz, A Golay, G T'Sjoen, B Delgado, I N El Ebrashy, E S Kang, C Wium, Bruce W. Bode, Ramazan Sari, B A Palchick, J Geohas, P R Nicol, M Winnie, N Aladağ, E W Braun, C Vercammen, S A Shelbaya, K Sivalingam, S Gorban de Lapertosa, E Riffer, F G Eliaschewitz, J B Buse, B Schultes, C H Sorli, K-W Lee, Mark Warren, T Pieber, S Stäuble, R Prager, A Mertens, A A Arif, D C Eagerton, A Scheen, I J Kim, J A Seo, S Ong, E Ataoglu, John B. Buse, D Berker, A White, F Helland, J C LaRocque, Young Min Cho, Christin L. Hertz, E M Palace, L H S Canani, M P Finneran, S H A Khalil, H L Gulseth, D Weiss, J Condit, E Fließer-Görzer, L Rista, S Akın, M H M F El Hefnawy, N H Kim, C Issa, S Bilz, H Bays, S Fischli, V Preumont, J Pereles-Ortiz, B Bode, E J Morawski, Aytekin Oguz, J Cooper, Tamer Tetiker, Ann Mertens, G Rudofsky, Thomas R. Pieber, W R Litchfield, J L Gross, D L Weinstein
Publikováno v:
The lancet. Diabetesendocrinology. 7(7)
BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglut
Autor:
Jessie L. Fahrbach, Sherry Martin, H. Jiang, Bruce H. R. Wolffenbuttel, R. Bhushan, L. J. Klaff
Publikováno v:
Diabetic Medicine, 26(11), 1147-1155. Wiley
AimsTo compare starter insulins in the elderly subgroup of the DURABLE trial 24-week initiation phase.MethodsIn a post-hoc analysis of the >= 65 years subgroup enrolled in the DURABLE trial, we compared the safety and efficacy of lispro mix 25 (LM25:
Autor:
H. D. Kay, R. Schneider, R. E. Harley, R. Brazg, L. J. Klaff, David A. D'Alessio, M. R. Ehlers, A. L. Mathisen
Publikováno v:
Hormone and Metabolic Research. 35:611-616
Aims: To evaluate the safety and efficacy of various doses of recombinant glucagon-like peptide-1 (7-36) amide (rGLP-1) administered subcutaneously (s. c.) via bolus injection or continuous infusion to lower fasting serum glucose (FSG) levels in subj
Autor:
Kurt, Ibrahim1 (AUTHOR), Krauhausen, Imke1,2 (AUTHOR), Spolaor, Simone1 (AUTHOR), van de Burgt, Yoeri1 (AUTHOR) y.b.v.d.burgt@tue.nl
Publikováno v:
Advanced Science. 7/17/2024, Vol. 11 Issue 27, p1-11. 11p.
Autor:
D. K. McCulloch, L. J. Klaff, S. E. Kahn, S. L. Schoenfeld, C. J. Greenbaum, R. S. Mauseth, E. A. Benson, G. T. Nepom, L. Shewey, J. P. Palmer
Publikováno v:
Diabetes. 39:549-556
Autor:
Stephanie A. Amiel, Sherwyn Schwartz, Simon Heller, David G. Maggs, Ian A. Macdonald, Orville G. Kolterman, Christian Weyer, L J Klaff, James A. Ruggles
Publikováno v:
Diabetes, obesitymetabolism. 7(5)
Background: Pramlintide, a human amylin analogue, is a potential new adjunctive therapy to insulin for patients with type 1 diabetes and insulin-using patients with type 2 diabetes. Early clinical trials have shown a transient increased risk of hypog
Autor:
L J Klaff, C. Corder, Alan Gottlieb, Sherwyn Schwartz, B. Levy, J. Peterson, Orville G. Kolterman
Publikováno v:
Diabetologia. 39(4)
Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin ana
Autor:
G. J. Taborsky, L. J. Klaff
Publikováno v:
American Journal of Physiology-Endocrinology and Metabolism. 252:E751-E755
It has been proposed that pancreatic somatostatin (SS) tonically inhibits pancreatic glucagon secretion. In keeping with this hypothesis, we have previously shown that infusion of a nonimmunoreactive analogue of SS, [D-Ala5,D-Trp8]somatostatin (SSa),
Publikováno v:
Gut. 24:642-647
The serum pancreatic polypeptide response to intravenous Boots secretin (1.5 U/kg), glucose tolerance, and insulin responses have been studied in 25 patients with chronic alcohol induced pancreatitis of varying severity, and these results compared wi
Autor:
C. Johnston, P. Raghu, D. K. McCulloch, J. C. Beard, W. K. Ward, L. J. Klaff, B. McKnight, R. N. Bergman, J. P. Palmer
Publikováno v:
Diabetes. 36:829-837